Altre lingue Ascendis Pharma A/S

Azioni

ASND

US04351P1012

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 06/02/2026			Variaz. 5gg	Var. 1 gen.
222,15 ^USD	+2,19%		-1,75%	+4,18%

06/02	Le azioni europee quotate negli Stati Uniti come American Depositary Receipts in forte rialzo nelle contrattazioni di venerdì; settimana stabile	MT
04/02	Ascendis Pharma pubblicherà i risultati finanziari dell'intero anno 2025 e fornirà un aggiornamento aziendale l'11 febbraio 2026	RE

Altre lingue

06/02	Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults
06/02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week
04/02	Ascendis Pharma to report full year 2025 financial results and provide business update on February 11, 2026
04/02	Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04/02	OPKO Health, Inc. and Entera Bio Ltd. Expand Partnership to Advance First-In-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
28/01	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading
26/01	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
26/01	National Medical Products Administration Approves Biologics License Application for Lonapegsomatropin for Injection
21/01	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
20/01	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
16/01	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week
12/01	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
10/01	Ascendis Pharma A/S : 44th Annual J.P. Morgan Healthcare Conference Presentation
10/01	Ascendis Pharma plans $120 million share repurchase program in 2026
10/01	Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
08/01	Ascendis Pharma A/S : COACH Trial Topline Week 52 Data
08/01	Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
08/01	Ascendis Pharma A/S Announces Topline Results from Week 52 of COACH Trial Evaluating Combination Therapy in Children with Achondroplasia
05/01	Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
26/12	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
24/12	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
22/12	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
18/12	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading
17/12	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
16/12	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue Ascendis Pharma A/S

Azioni

ASND

US04351P1012

Biotecnologia

Altre lingue

Filtri